Skip to Content

Elmiron (pentosan polysulfate sodium) Disease Interactions

There are 2 disease interactions with Elmiron (pentosan polysulfate sodium):

Moderate

Pentosan polysulfate sodium (Includes Elmiron) ↔ bleeding

Moderate Potential Hazard, Moderate plausibility. Applies to: Thrombocytopathy, Bleeding, Coagulation Defect, Thrombocytopenia

Pentosan polysulfate sodium induces weak anticoagulant activity (1/15 the activity of heparin). Bleeding complications (ecchymosis, epistaxis, bleeding gums) have occurred. Increases in PT and PTT, as well as thrombocytopenia, have been reported rarely. Therapy with pentosan polysulfate sodium should be administered cautiously in patients with coagulation disorders, bleeding, or other conditions that may increase the risk for bleeding.

References

  1. Tardy-Poncet B, Tardy B, Grelac F, Reynaud J, Mismetti P, Bertrand JC, Guyotat D "Pentosan polysulfate-induced thrombocytopenia and thrombosis." Am J Hematol 45 (1994): 252-7
  2. "Product Information. Elmiron (pentosan polysulfate sodium)." Baker Norton Pharmaceuticals, Miami, FL.
  3. Goad KE, Horne MK 3rd, Gralnick HR "Pentosan-induced thrombocytopenia: support for an immune complex mechanism." Br J Haematol 88 (1994): 803-8
Moderate

Pentosan polysulfate sodium (Includes Elmiron) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of pentosan polysulfate sodium has not been studied in patients with hepatic insufficiency. Because there is evidence of hepatic contribution to the elimination of this drug, hepatic impairment may have an impact on its pharmacokinetics. Caution should be exercised when using pentosan polysulfate sodium in this patient population.

References

  1. "Product Information. Elmiron (pentosan polysulfate sodium)." Baker Norton Pharmaceuticals, Miami, FL.
  2. MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M "Metabolism of sodium pentosan polysulphate in man--catabolism of iodinated derivatives." Thromb Haemost 51 (1984): 321-5
  3. Peters M, Witvrouw M, De Clercq E, Ruf B "Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients." AIDS 5 (1991): 1534-5

Elmiron (pentosan polysulfate sodium) drug interactions

There are 71 drug interactions with Elmiron (pentosan polysulfate sodium)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.